Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Aarcoron Sep 25, 2015 11:48am
176 Views
Post# 24135486

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:someone wants this stock.........

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:someone wants this stock.........Let me be clear about another point.  I'm not arguing that the $1.40 lid is sound.  In fact, I think it's a very risky venture when one considers that trying to grind out a 20-35% profit off a private placement issued by a pre-clinical biotech with one technology is pretty much asking for trouble.  The almost binary outcome in the short term (one year) is 20-35% gain or 95% loss.  Not the kind of odds risk managers like to see.

What I've observed over time is a relatively routine daily distribution that suggests the likely 20-35% gain is the plan, at least for some (one?) big shareholder and if that suits his risk profile, so be it.  If all works well, they'll/he'll be left with what will be a solid gain in 2015, little stock, and a big handful of risk-free warrants waiting to be exercised for the potential home run.

And yes, if that daily distribution wasn't happening, I could speculate that the share price might be between $2 and $3 today.  And also, I agree completely that there should have been no forced exercise attached to the warrants.



Bullboard Posts